CSIMarket


Astria Therapeutics inc   (ATXS)
Other Ticker:  
 


 

Astria Therapeutics inc

ATXS's Financial Statements and Analysis



Astria Therapeutics inc narrowed first quarter of 2024 net loss per share of $-0.38 compare to net loss per share of $-0.40 recorded in the same quarter a year ago and improved compare to net loss per share of $-0.62 realized in previous quarter.


first quarter of 2024
Earnings Per Share Revenues
$ -0.38 $  0 Mill
$+0.02     Unch.    



Astria Therapeutics Inc 's Revenue fell by 0 % in first quarter of 2024 (Mar 31 2024) year on year, to $0 million and declined by sequentially.


Astria Therapeutics Inc is

More on ATXS's Income Statement



Astria Therapeutics Inc in the first quarter of 2024 recorded net loss of $-19.928 million, an increase from net loss of $-11.188 million in I. Quarter a year ago.

Sequentially net loss narrowed from net loss of $-31.410 million realized in previous quarter.

More on ATXS's Growth

Astria Therapeutics Inc Inventories
In Mar 31 2024 company's net cash and cash equivalents decreased by $-4 million


Astria Therapeutics inc does not pay out common stock dividend.

In trailing twelve-month period Astria Therapeutics inc payed $ -1.42 cash per share, on a free-cash flow basis .

Book value fell by -12.88 % sequentially to $7.03 per share, -50.01% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 7.03 per share from $ 8.07.

Company issued 22.17 million shares or 73.62 % in Mar 31 2024.


More on ATXS's Dividends

 Market Capitalization (Millions) 502
 Shares Outstanding (Millions) 52
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -82
 Cash Flow (TTM) (Millions $) -30
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 10




Astria Therapeutics inc does not pay out common stock dividend.

In trailing twelve-month period Astria Therapeutics inc had negative $ -1.42 cash flow per share, on a free-cash flow basis .

Book value fell by -12.88 % sequentially to $7.03 per share, -50.01% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 7.03 per share from $ 8.07.

Company issued 22.17 million shares or 73.62 % in Mar 31 2024.


More on ATXS's Balance Sheets

 Market Capitalization (Millions) 502
 Shares Outstanding (Millions) 52
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -82
 Cash Flow (TTM) (Millions $) -30
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 10
   


  News about Astria Therapeutics inc Earnings

2. Rising Operating Deficit Raises Concerns for Astria Therapeutics Inc. 3. Promising Developments in Drug Pipeline Offer Hope for Astria Therapeutics Inc.

The financial results of Astria Therapeutics Inc (NASDAQ: ATXS) for the first quarter of 2024 reveal a concerning trend of widening operating deficit. The operating deficit for this quarter was reported at $-24.15 million, significantly higher than the deficit of $-13.493 million in the same period of 2023. Furthermore, the net deficit has also increased from $-11.188 million in the first quarter of the prior year to $-19.928 million in the current quarter. These figures signify a deterioration in the financial performance of the company.
On the other hand, Astria Therapeutics Inc has shown promise with the development of STAR-0215, a potential preventative therapy for Hereditary Angioedema (HAE). The co...

2 CEO Jill C. Milne's Optimism and Commitment to Innovation Drive Astria Therapeutics Inc. Forward

The recent financial results of Astria Therapeutics Inc, a key player in the Major Pharmaceutical Preparations industry, have been a topic of interest among investors and industry experts alike. Despite reporting a net deficit and operating shortfall for the financial period ending December 31, 2023, the company remains optimistic about its future prospects. With a focus on developing groundbreaking therapies for allergic and immunological diseases, Astria Therapeutics has shown resilience and determination in a challenging market environment.
CEO Jill C. Milne's confidence in STAR-0215 as a potential game-changing preventative therapy for Hereditary Angioedema (HAE) is not to be underestimated. The comp...

Astria Therapeutics Inc Emerges as Leading Player with Impressive Third Quarter Results Amidst Fierce Market Competition

Astria Therapeutics Inc, a biopharmace...

Astria Therapeutics Inc Faces Mounting Expenditures: A Glimpse into the Alarming Q2 2023 Earnings Report

Astria Therapeutics Inc: An In-depth Look at Recent Financial Performance
Astria Therapeutics Inc, a major player in the pharmaceutical industry, is currently facing some challenges in their financial performance. Shareholders have been keeping a close eye on the company's operating shortfall, which has recently worsened. This article aims to provide an extensive examination of Astria Therapeutics Inc's financial situation and shed some light on investors' concerns.
The reporting cycle from April to June 2023 revealed an operating shortfall of -$15.102 million, compared to -$11.449 million in the same period of 2022. This significant increase in operating shortfall has raised questions among investor...

ATXS Overcomes Adversity: Operating Deficit Shrinks to $-15.378 Million in Q1 2023

As the Major Pharmaceutical Preparations industry continues to dominate the headlines, it's worth noting that there are a number of lesser-known corporations that are also making waves in the market. In particular, Astria Therapeutics Inc has recently published its earnings report for the first quarter of 2023, indicating that the company has experienced an operating deficit of $-13.493 million.
Despite this deficit, there are some positive signs for the company. For one, Astria Therapeutics' financials have improved significantly over the past year. In the same period last year, the company had an operating deficit of $-15.378 million, which suggests that the company is continuing to compete more effect...


Date modified: 2024-05-11T11:46:07+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com